2026 Global: Copd And Asthma Devices Market -Competitive Review (2032) report
Description
The 2026 Global: Copd And Asthma Devices Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Major players in the COPD and asthma devices market include GlaxoSmithKline (GSK), Boehringer Ingelheim, AstraZeneca, and Novartis. GSK, headquartered in London, United Kingdom, markets a broad portfolio of inhaler devices, including the Diskus dry powder inhaler and the Ellipta family, which accompany its fluticasone propionate/salmeterol and other corticosteroid combinations. Boehringer Ingelheim, based in Ingelheim am Rhein, Germany, co-develops and markets device-enabled therapies such as Spiriva HandiHaler and Spiriva Respimat, reinforcing its integrated approach to bronchodilator therapy. AstraZeneca, headquartered in Cambridge, United Kingdom, offers Symbicort and other inhaled regimens that rely on widely used pressurized metered-dose or dry powder devices, extending its presence in asthma and COPD management. Novartis, headquartered in Basel, Switzerland, has advanced inhalation products such as Ultibro Breezhaler, contributing to LAMA/LABA regimens, and engages in device development to optimize aerosol delivery. Collectively, these firms anchor inhaler technology through proprietary platforms, regulatory approvals, and global manufacturing networks. Worldwide operations.
Sanofi, headquartered in Paris, France, extends its respiratory device portfolio through inhalers and spacer systems designed to optimize aerosol delivery in asthma and COPD. The company collaborates on combination therapies and device compatibility, aligning regulatory strategies with global markets. Teva Pharmaceutical Industries, headquartered in Petah Tikva, Israel, supplies generic and branded inhalation products, including pressurized metered-dose inhalers and nebulizers, expanding access in multiple geographies. Vectura Group, headquartered in Chippenham, United Kingdom, focuses on inhalation device design and development, partnering with pharmaceutical brands to advance dry powder inhalers, soft mist inhalers, and nebulization platforms, while maintaining a pipeline oriented toward efficient drug delivery. PARI GmbH, headquartered in Starnberg, Germany, specializes in compact nebulizers and mesh nebulizers, supporting both prescription and OTC therapies for COPD and asthma and serving clinical and consumer markets. Together, these firms diversify device platforms through engineering, material science, and strategic alliances that complement the broader pharmaceutical portfolios.
Chiesi Farmaceutici, headquartered in Parma, Italy, advances inhalation technology through specialization in pediatric and adult respiratory care, including pressurized inhalers and nebulizer-compatible formulations, often emphasizing device optimization to improve adherence and deposition. The privately held company collaborates with contract manufacturers and research institutes to expand access to innovative delivery systems, particularly for corticosteroid and bronchodilator combinations. Philips, Koninklijke Philips N.V., headquartered in Amsterdam, Netherlands, supplies broad hardware and software solutions for respiratory care, ranging from home nebulizers and oxygen therapy devices to connected inhaler monitoring platforms. Through its respiratory care division, Philips integrates patient education, adherence support, and data-enabled management to complement drug delivery. Collectively, these companies broaden the COPD and asthma devices landscape by bridging device engineering with pharmacotherapy, enabling compatible, patient-centered delivery across healthcare settings. The market thus displays a continuum from specialized device developers to diversified technology conglomerates, each contributing to improved aerosolization, compliance, and clinical outcomes.
Major players in the COPD and asthma devices market include GlaxoSmithKline (GSK), Boehringer Ingelheim, AstraZeneca, and Novartis. GSK, headquartered in London, United Kingdom, markets a broad portfolio of inhaler devices, including the Diskus dry powder inhaler and the Ellipta family, which accompany its fluticasone propionate/salmeterol and other corticosteroid combinations. Boehringer Ingelheim, based in Ingelheim am Rhein, Germany, co-develops and markets device-enabled therapies such as Spiriva HandiHaler and Spiriva Respimat, reinforcing its integrated approach to bronchodilator therapy. AstraZeneca, headquartered in Cambridge, United Kingdom, offers Symbicort and other inhaled regimens that rely on widely used pressurized metered-dose or dry powder devices, extending its presence in asthma and COPD management. Novartis, headquartered in Basel, Switzerland, has advanced inhalation products such as Ultibro Breezhaler, contributing to LAMA/LABA regimens, and engages in device development to optimize aerosol delivery. Collectively, these firms anchor inhaler technology through proprietary platforms, regulatory approvals, and global manufacturing networks. Worldwide operations.
Sanofi, headquartered in Paris, France, extends its respiratory device portfolio through inhalers and spacer systems designed to optimize aerosol delivery in asthma and COPD. The company collaborates on combination therapies and device compatibility, aligning regulatory strategies with global markets. Teva Pharmaceutical Industries, headquartered in Petah Tikva, Israel, supplies generic and branded inhalation products, including pressurized metered-dose inhalers and nebulizers, expanding access in multiple geographies. Vectura Group, headquartered in Chippenham, United Kingdom, focuses on inhalation device design and development, partnering with pharmaceutical brands to advance dry powder inhalers, soft mist inhalers, and nebulization platforms, while maintaining a pipeline oriented toward efficient drug delivery. PARI GmbH, headquartered in Starnberg, Germany, specializes in compact nebulizers and mesh nebulizers, supporting both prescription and OTC therapies for COPD and asthma and serving clinical and consumer markets. Together, these firms diversify device platforms through engineering, material science, and strategic alliances that complement the broader pharmaceutical portfolios.
Chiesi Farmaceutici, headquartered in Parma, Italy, advances inhalation technology through specialization in pediatric and adult respiratory care, including pressurized inhalers and nebulizer-compatible formulations, often emphasizing device optimization to improve adherence and deposition. The privately held company collaborates with contract manufacturers and research institutes to expand access to innovative delivery systems, particularly for corticosteroid and bronchodilator combinations. Philips, Koninklijke Philips N.V., headquartered in Amsterdam, Netherlands, supplies broad hardware and software solutions for respiratory care, ranging from home nebulizers and oxygen therapy devices to connected inhaler monitoring platforms. Through its respiratory care division, Philips integrates patient education, adherence support, and data-enabled management to complement drug delivery. Collectively, these companies broaden the COPD and asthma devices landscape by bridging device engineering with pharmacotherapy, enabling compatible, patient-centered delivery across healthcare settings. The market thus displays a continuum from specialized device developers to diversified technology conglomerates, each contributing to improved aerosolization, compliance, and clinical outcomes.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
